Caydan portfolio company MitoSense signs research collaboration MOU with University of Pittsburgh

  • Caydan Capital Partners portfolio company MitoSense signed an MOU with the University of Pittsburgh to explore joint research in space biomedicine, mitochondrial biology, and long COVID.
  • Collaboration focus includes biomarker discovery, multiomics analysis, computational pipeline development, publications, and working groups tied to astronaut health and post-viral disease.
  • The MOU runs for three years; any funded programs, IP terms, or commercialization plans would be set in separate definitive agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caydan Capital Partners published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.